Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis.

ABSTRACT:

Introduction

Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder associated with significant morbidity and mortality. Cardiac myosin inhibitors (MIs), including mavacamten and aficamten, offer a novel therapeutic approach for HCM.

Methods

An online database search was performed from inception to September 2024. We selected randomized controlled trials (RCTs) that compared mavacamten with placebo/guideline medical treatment for HCM.

Results

Six RCTs involving 1,081 participants were analyzed. Cardiac myosin inhibitors significantly reduced left ventricular outflow tract (LVOT) gradients at rest (-70.22 mm Hg, 95% CI: -85.42 to -55.03) and during the Valsalva maneuver (-61.44 mm Hg, 95% CI: -71.10 to -51.78). Patients experienced improved functional s

SUBMITTER: Hazique M 

PROVIDER: S-EPMC12828646 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature